<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: In a previous study from our laboratory, ritanserin, a specific 5-HT2 <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, reduced ischemic damage in the setting of transient global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined the effect of ritanserin on ischemic cerebral blood flow, systemic blood pressure, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the model of permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with brain temperature controlled at 35.0 degrees C to 36.0 degrees C </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Thirty-seven male Sprague-Dawley rats were used </plain></SENT>
<SENT sid="3" pm="."><plain>The right middle cerebral artery was permanently occluded </plain></SENT>
<SENT sid="4" pm="."><plain>Ritanserin (8 mg/kg) or vehicle was continuously administered intravenously for 90 minutes starting 10 minutes after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Cerebral blood flow was monitored by laser Doppler flowmetry in the ischemic cortex before and for 2 hours after <z:mp ids='MP_0006134'>arterial occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Brains were perfusion-fixed 3 days later, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were measured </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Mean arterial blood pressure was not affected by treatment </plain></SENT>
<SENT sid="8" pm="."><plain>In the vehicle and ritanserin groups, mean ischemic cerebral blood flow (percent of preischemic values) was 34.6 +/- 14.7% (mean +/- SD) and 26.6 +/- 15.0%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Hemispheric <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were 119.3 +/- 49.4 mm3 and 136.6 +/- 49.6 mm3, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>No significant differences were recognized </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Intravenous administration of ritanserin did not affect mean arterial blood pressure or cerebral blood flow in the ischemic region during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>No protective effect of ritanserin was apparent in the setting of permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> when treatment was begun shortly after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>